Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) posted its earnings results on Thursday. The biotechnology company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01), FiscalAI reports. The company had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS delivered strong momentum: Q2 U.S. net sales rose 14% year over year to $282.3 million, supported by mid-single-digit prescription growth and improved net pricing. Ironwood raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion, implying growth of more than 30% and a return to blockbuster status.
• The FDA approved LINZESS for functional constipation in pediatric patients aged two and older, making it the only prescription therapy approved for this age group and expanding the brand’s addressable patient population.
• Ironwood initiated active enrollment in the confirmatory Phase III STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure. Management believes the once-weekly therapy’s efficacy, tolerability, and potential to reduce parenteral-support dependence could support a best-in-class profile, though enrollment remains an execution priority.
• Q2 GAAP net income was $51 million and adjusted EBITDA was $83 million; full-year revenue guidance increased to $460 million–$485 million and adjusted EBITDA guidance to above $310 million. The company repaid $200 million of convertible notes and expects gross debt below $300 million and leverage below 1x by year-end.
• R&D spending is expected to rise in the second half as STARS-2 enrollment and site activation ramp, with modestly higher SG&A also anticipated. The ultimate expense increase will depend on how quickly additional trial sites are brought online.

Ironwood Pharmaceuticals Stock Up 1.4%

IRWD stock traded up $0.06 during trading on Friday, reaching $4.32. 1,842,560 shares of the company’s stock were exchanged, compared to its average volume of 2,179,845. Ironwood Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $5.78. The firm has a market cap of $704.41 million, a PE ratio of 5.61 and a beta of 0.20. The company’s fifty day moving average price is $3.90 and its 200-day moving average price is $3.97.

Analysts Set New Price Targets

A number of research firms recently issued reports on IRWD. Wall Street Zen lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. Finally, Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.23.

Insiders Place Their Bets

In related news, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares in the company, valued at $935,293.77. The trade was a 7.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the sale, the insider owned 313,680 shares in the company, valued at approximately $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 9.30% of the stock is currently owned by company insiders.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its holdings in Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after acquiring an additional 8,337,672 shares during the last quarter. Millennium Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 144.3% in the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,975,939 shares of the biotechnology company’s stock worth $16,769,000 after purchasing an additional 58,603 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Ironwood Pharmaceuticals by 40.7% in the 4th quarter. Marshall Wace LLP now owns 4,424,002 shares of the biotechnology company’s stock worth $14,909,000 after purchasing an additional 1,279,863 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.